Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
link
photo
Tags
avapritinib
biotech
blueprint medicines
boston
boston blog main
boston top stories
clinical trials
cstone pharmaceuticals
deals
eli lilly
european medicines agency
fda
fisogatinib
flatiron health
genentech
hepatocellular carcinoma
investing
jeff albers
life sciences
medullary thyroid cancer
national blog main
national top stories
non-small cell lung cancer
pralsetinib
roche
san francisco blog main
san francisco top stories
selpercatinib
thermo fisher scientific
thyroid cancer
What
approval
2
×
currently
2
×
drug
accessibility
approved
blueprint
cancer
candidate
cannabis
cbd
dea
epilepsy
epileptic
fast
fda
huge
impact
marketing
medication
medicines
muscle
nationwide
pact
patients
person
regulatory
reschedule
ret
review
roche
schedule
sold
team
tracked
treatment
use
wins
writer's
Language
unset
Current search:
currently
×
approval
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@WIRED
6 years ago
Currently, CBD is a Schedule 1 drug like cannabis, and the DEA must reschedule it before the epilepsy medication can be sold. If approved, this would have ...
